Focus: Amgen is a $28.2B revenue, California-based biotechnology leader focused on small molecules and biologics across oncology, cardiovascular, bone health, immunology, and neuroscience. With 27,000 employees and a 44-year history as a public company, it ranks among the world's largest independent biotech firms.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Hot — 4963 jobs added in 30d
Net +4003 (4963 new, 960 removed). Aggressive expansion phase.
2 recent layoff filings (12 mo) — 100 affected
Source: state DOL filings via Big Local News
Amgen offers strong financial stability and career depth for established biotech professionals, but revenue concentration and recent operational headwinds warrant careful evaluation of role stability and team tenure.
Amgen's anchor product representing 44% of total revenue; approaching loss of exclusivity creates significant downstream commercial and R&D restructuring risk.
Help build intelligence for Amgen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Amgen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Specialty therapeutic with niche indication but approaching patent expiry; revenue stable but erosion likely within 5 years.
Next-generation targeted oncology asset with extended LOE (2040); represents Amgen's pivot toward precision medicine and long-term revenue stability.
Mature small-molecule dermatology product; patent cliff in 2030 creates near-to-mid-term revenue erosion risk of $135M.
First-in-class IGF-1R inhibitor for rare disease with strong clinical differentiation; no near-term LOE extends commercial runway.
Rare disease niche product with patent cliff in 2030; represents Amgen's specialist portfolio but modest revenue scale.
Legacy biologic ESA with mature market; approaching LOE and biosimilar competition signal declining commercial relevance.
Cardiovascular small molecule with earliest patent cliff (June 2027); immediate generic threat creates near-term sales erosion.
Oncology/bone health indication of same mechanism as PROLIA; portfolio overlap and approaching LOE amplify revenue consolidation risk.
Legacy biologic G-CSF with mature market and biosimilar competition; approaching LOE signals waning commercial relevance.
11 discontinued, 10 duplicate formulations not shown
+11 more products with revenue data
+2 more
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs - 24/7 Wall St.
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs 24/7 Wall St.
Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
Global pharma companies that have publicly announced Trump drug pricing agreements Reuters
Amgen court case may heighten scrutiny of patent deals in pharmaceuticals — STAT News - UA.NEWS
Amgen court case may heighten scrutiny of patent deals in pharmaceuticals — STAT News UA.NEWS
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen? - 24/7 Wall St.
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen? 24/7 Wall St.
France recalls rare disease drug Tavneos after deaths - France 24
France recalls rare disease drug Tavneos after deaths France 24
Pharma in hackers' crosshairs as Amgen breach moves to courts - The Pharma Letter
Pharma in hackers' crosshairs as Amgen breach moves to courts The Pharma Letter
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent layoffs across manufacturing and non-manufacturing functions signal potential organizational restructuring; combined with cybersecurity breach (August 2026), near-term role stability warrants inquiry into specific team plans and leadership tenure.
Recent peer-reviewed publications with author affiliations at this company
+5 more products
+2 more
+2 more
+2 more
+2 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo